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Introduction
Glioblastoma (GBM) is the most common and most malignant primary brain tumor in adults with high recurrence rates even after a complete resection. New GBM therapeutic strategies are desperately needed, requiring insights into the biological and molecular mechanisms controlling glioma growth. GBMs are complex tumors that display cellular heterogeneity within the tumor mass. Several studies suggest that GBMs contain a subpopulation with tumorigenic potential and stem cell characteristics (1) (2) (3) (4) (5) . These glioma stem cells (GSCs) play key roles in the growth, invasion, angiogenesis and immune evasion of glioma (6, 7) . They have also been identified as the major cellular entity for conferring chemo-and radioresistance (3, 8, 9) , and have thus emerged as a new therapeutic target. GSCs express neural stem cell markers such as nestin, SOX2, and Musashi-1 (2) . In addition, CD133 is an enrichment marker for GSCs, however several studies have demonstrated its limitations as a specific marker (10, 11) . A functional feature of GSCs is their ability to form neurospheres in the culture medium containing B27 supplement and defined growth factors, such as epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF).
To identify GSCs, we tested for their ability to form neurospheres in combination with cell sorting using CD133.
A perivascular niche has been proposed for GSC that determines the characteristics of GSCs and controls the malignant behaviour of tumor cells (12) . However, there is only limited knowledge about the composition of the GSC niche. Inflammatory mediators and inflammatory cells are indispensable components of the neoplastic microenvironment (13) . Glioma-associated microglia (GAMs), the brain-resident macrophages, together with blood-borne monocytes are the predominant cells, contributing up to 30% of the total tumor mass (14) and their abundance is positively correlated with glioma malignancy (15) . Tumor secreted CXCL12 (stromal cellderived factor-1, SDF-1) is a potent microglia and macrophage recruiting molecule, especially for 5 attracting GAMs to hypoxic areas (16) . Activation of SDF-1 and its receptor CXCR4 have been shown to promote macrophage mobilization and tumor revascularization (17) . Despite their cytotoxic and phagocytic potential (18) , these GAMs rather support tumor growth. Depletion of microglia reduced glioma invasion in organotypic brain slices (19) and also decreased glioma expansion in vivo (20) . Microglia release many factors, including extracellular matrix proteases and cytokines, which directly or indirectly influence tumor migration and proliferation (21) . We have previously shown that glioma-triggered microglial MT1-MMP and MMP9 expression via Toll like receptor (TLR)2 is one of the mechanisms for microglia-induced tumor expansion (20, 22, 23) . TLRs are the main members of the pattern recognition receptor (PRR) family that are necessary for the induction of an innate immune response to damage-associated molecular patterns (DAMPs) through the activation and maturation of macrophages and dendritic cells (24) .
Microglia have been reported to be the predominant TLR-expressing cell type in the normal CNS (25) as well as in the glioma tissue (23) . Microglia/brain macrophages freshly isolated from human glioma tissue also express substantial levels of TLR2, TLR3 and especially TLR4 (26) .
Interleukin (IL)-6 is a cytokine secreted after TLR activation and its expression has been shown to correlate with glioma invasiveness (27) . It also plays a major role in the response to injury or infection and is involved in the immune response, inflammation, and hematopoiesis (28) . Glioma cells have been reported to secrete IL-6 (29, 30) and express IL-6 receptors (27) . Glioma-derived IL-6, working together with other tumor-secreted factors such as TGF-ß and PGE2, polarize glioma-infiltrating microglia toward an anti-inflammatory phenotype (21) and microglia-derived IL-6 has been reported to induce glioma cell migration and invasiveness (30) .
In this research we have investigated the link between microglial IL-6 production, TLR expression and the potential of tumor stem cells to form glioma by utilizing two glioma murine models and human samples.
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Materials and Methods
Animals
All experiments were carried out using C57BL/6J WT mice (Charles River Laboratories, Sulzfeld, Germany) or TLRs 2, 4, 7, 9 and MyD88 -/-on a C57BL/6J background. The TLR knockout mice were generated by Dr. Shizuo Akira and colleagues from the Osaka University, Japan and obtained from Oriental BioServices Inc., Japan (22) . The generation of IL-6 knockout mice (IL-6 -/ -) has been described in detail previously (31) . Briefly, IL-6 deficient mice had been backcrossed on a C57BL/6J background for >10 generations (32) . To broaden the relevance of our findings, we employed another murine model where the tumor is initiated by the overexpression of PDGFb in Nestin-expressing cells in vivo: Ntv-a/Ink4a-Arf -/-mice develop high-grade gliomas, which reflect features of the pro-neural subtype in human GBMs(33-35), 6 to 8 weeks following intracranial injection of RCAS-PDGFb-producing DF-1 chicken fibroblast cells at 4.5 to 10 weeks of age (36, 37) . The mice were bred and maintained in the animal housing facilities of the Max Delbrück Center for Molecular Medicine and Charité university hospital (Berlin, Germany) as per rules of the local governmental institutions (LaGeSo, G 0268/10, G 0343/10, G 0438/12). The mice were housed with a 12 h/12 h light-dark cycle and received food and water ad libitum.
Human materials
All human glioma materials in this study were obtained from the Department of Neurosurgery at
Charité University Hospital according to the rules of the Ethical Committee (Charité, EA4/098/11).
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Cell culture
The murine GL261 glioma cell line (which is isogenic to C57BL/6J mice; National Cancer Institute, Frederick, MD), rat glioma cell line C6 (American Type Culture Collection, ATCC, Teddington, UK) and human glioma cell line U87 (ATCC) were grown in DMEM with 10%
FCS, 200 mM glutamine, 100 U/ml penicillin, and 100 ng/ml streptomycin (Invitrogen, Darmstadt, Germany). EGFP GL261 cells were generated as previously described (22) .
NCH421K is a primary human glioblastoma cell line, which is highly enriched in CD133 + GSCs (38) . NCH421K cells (CLS Cell Lines Service GmbH, Eppelheim, Germany) were grown in stem cell medium consisting of Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12
(DMEM / F-12; Invitrogen, Carlsbad, CA) containing supplement (2% B27; Invitrogen), growth factors (20ng/ml EGF and bFGF; from PeproTech, Hamburg, Germany) and additives (100 U/ml penicillin, and 100 mg/ml streptomycin; all from Invitrogen). Neonatal microglial cells were prepared from WT, MyD88 -/-and TLRs 2, 4, 7 and 9 -/-mice according to previously established protocols (22) . Microglia were also cultured from adult mice (P49-P56) as previously described in detail (39 
Isolation and cell culture of glioma stem cells
Mouse glioma stem cells were isolated from the GL261 cell line as previously described(40). In summary, bulk cultures of GL261 cells were grown in stem cell medium for at least 4-6 weeks.
To broaden the relevance of our findings, we employed the RCAS-PDGFb murine tumor model. 
RCAS-
Multiple analyte detection and ELISA
Multiple analyte detection of cytokines and chemokines in supernatants was performed using according to the manufacturer's manual.
TLR4 antibody treatment
For the treatment with a TLR4 antibody, anti-mouse MTS510 or isotype control (both from eBioscience) was applied to the medium after seeding primary cultured neonatal microglia to incubate overnight, and new antibody or isotype was added when the medium was changed to stimulate with GCM.
Magnetic cell separation of human brain tumor tissue
Glioma associated brain microglia/macrophages were isolated from the human tumor resected tissues. Fresh tissue was dissociated immediately after resection using the neural tissue dissociation kit (MiltenyiBiotec, Bergisch Gladbach, Germany). Erythrocytes were lysed by adding 5 ml ammonium chloride solution for 10 min. Next, cells were resuspended in PBS containing 0.5% bovine serum albumin and 2mM ethylenediaminetetraacetic acid (EDTA).
Magnetic sorting for CD11b + cells was then performed using a CD11b MicroBead kit (MiltenyiBiotec) following the manufacturer's instruction. Magnetic activated cell sorting (MACS) into CD11b -and CD11b + enriched cell populations was carried out using several MACS columns in a series. Both CD11b -and CD11b + fractions were collected. A purity check was performed after MACS separation by flow cytometry analysis of a small fraction of the sorted populations.
Real-time qPCR
Total RNA was isolated from microglia obtained from WT mice, as well as from CD133 + and CD133 -FACS sorted GL261 cells and MACS purified microglia from human GBM tissue using
Invitrap Spin Universal RNA mini kit (Invitek GmbH, Berlin, Germany). Quality and yield were determined by NanoDrop ND-1000 (Thermo Scientific, Schwerte, Germany 
Flow cytometry
Fluorescence-activated cell sorting (FACS) analysis was carried out on a LSR Fortessa 5Laser
(BD Biosciences, Erembodegem, Belgium). Cell sorting was carried out using a FACS-Aria-II 
In vivo glioma implantation
Wild type and IL-6 -/-mice were used for the in vivo studies to investigate glioma expansion. To broaden the relevance of our findings, 4.5 to 10-week-old (Ntv-a/Ink4a-Arf -/-mice for DF-1 RCAS-PDGFb injection) were used to culture RCAS GSCs. Surgical procedures were performed as described (41, 42) . Briefly, mice were anesthetized, immobilized and mounted onto a 
Immunofluorescent staining and image processing
Free-floating 40 µm thick brain sections from tumor-bearing mice were prepared as previously described (22) . Nuclei were visualized using 4,6-diamidino-2-phenylindole (DAPI) from SigmaAldrich. The GL261 glioma cells were identified by green fluorescence of the EGFP construct. 
Statistical analysis
All data represent the average of at least 3 independent experiments. Datasets were analyzed statistically with SPSS11.5 software and tested for normality with the Shapiro-Wilks test. The
Mann-Whitney U test was used for nonparametric analysis. Parametric testing was done with the Student t test. Comparisons between multiple groups were done using 1-way ANOVA with the Scheffe´ post hoc test. Statistical significance was determined at P values <.05 (*) and <.01 (**) while "n.s." implied a non significant P value.
Results
IL-6 deficient mice show reduced glioma growth
To investigate whether ablation of the IL-6 gene locus in the host interfered with tumor expansion in vivo, we implanted EGFP-GL261 cells into WT and IL-6 -/-mice and measured glioma volume by unbiased stereological estimation (Cavalieri method These data indicate that IL-6 from the host cells supports tumor growth by GSCs, but not by bulk glioma cells.
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Microglial IL-6 is upregulated by supernatant from glioma stem cells but not from bulk glioma cells
To investigate the potential of GSCs versus bulk cells to induce microglial cytokine release, mouse primary neonatal microglia cultures were treated with control medium (stem cell culture medium) or supernatant medium from GL261 cells (GCM) either enriched for CD133 or deprived of CD133. After 24 hours of stimulation, cell supernatant was collected to measure expression levels of 12 cytokines. As shown in Fig. 2 , the level of IL-6 in supernatant from microglial cells that were stimulated with CD133 + conditioned medium was higher than the levels in supernatant from microglial cells that were stimulated with CD133 -conditioned medium control. After 24 hours of treatment, cell supernatant was collected to perform ELISA for three pro-inflammatory cytokines: IL-6, TNF-α and IL-1β. As shown in Fig. 3 , the level of IL-6 in supernatant from microglial cells that were stimulated with CD133 + or neurosphere GL261
conditioned medium was higher than the levels in supernatant from microglial cells that were stimulated with CD133 -or adhesive GL261 conditioned medium (control: 0.67±0.22ng/ml, 
Factors released from glioma stem cells induced microglial IL-6 secretion through MyD88-
TLR4 signaling
We have previously shown that glioma-released versican induced microglial MT1-MMP production through the TLR2 signaling pathway (23) . We therefore tested whether IL-6 release is also regulated by TLR signaling. Since MyD88 is the adapter protein for all TLRs except TLR3(44), we stimulated microglia from MyD88 -/-animals with GSC supernatant. The TLR3 agonist Poly I:C was used as a positive control. As shown in Fig. 4A , in microglial cells deficient for MyD88, IL-6 induction was completely abolished, indicating that GSCs triggered microglial IL-6 induction through TLR signaling. We then screened GSC-triggered microglial IL-6 induction in TLR2, TLR4, TLR7 and TLR9 -/-animals. Interestingly, only the knockout of TLR4 impaired microglial IL-6 induction (control: 0.2±0.08ng/ml, CD133 + : 0.24±0.07ng/ml, neurosphere GL261: 0.23±0.04ng/ml, Fig. 4B ) while IL-6 upregulation was similar to wild type levels in microglial cells from TLR2-, TLR7-or TLR9-deficient animals (Fig. 4D, 4E and 4F ).
The TLR4 monoclonal neutralizing antibody MTS510 has previously been shown to functionally block TLR4 (45) . We first verified that MTS510 blocks microglial TLR4 functionality in vitro.
MTS510 attenuated the TLR4 agonist LPS-induced microglial IL-6 induction (Fig. 4C) . However, from this data tenascin-C is the best candidate to be investigated further in order to verify its role in IL-6 upregulation after TLR4 stimulation in microglia cells by soluble factor derived from CD133 + cells (see scheme in Fig. 6 ).
GAMs are predominating IL-6 expressing population in gliomas
To evaluate the potential contribution of IL-6 signaling to the glioma microenvironment, we measured IL-6 release in a series of glioma cell lines as well as mouse microglia and microglia stimulated from conditioned medium of CD133 -and CD133 + GL261 cells. While some of the gliomas do secrete IL-6, both CD133 -and CD133 + GL261 cells express very low level of IL-6 compared to naïve microglia and microglia primed by CD133 + GL261 conditioned medium ( 0.64±0.27ng/ml, CD133 + : 3.28±0.5ng/ml, p=0.03). To verify that the IL-6 receptor is expressed on the target cell, we measured IL-6 receptor expression in primary cultured neonatal microglia and freshly FACS isolated CD133 + and CD133 -GL261 cells by qRT-PCR (Fig. 5B) . CD133 + cells expressed higher IL-6 receptor and gp130 mRNA levels than CD133 -cells or microglial
cells. These data demonstrate that the expression of IL-6 receptors was elevated on CD133 + in comparison to CD133 -cells, and supports the concept of paracrine signaling between GSCs and microglia ( Fig. 6) . We also purified microglia/brain macrophages from human GBM tissue by MACS (the purity of CD11b + cells was described previously (46)) and tested for the expression of IL-6 by qRT-PCR. In 7 out of 8 samples, the CD11b + cells (i.e. GAMs) expressed higher IL-6 than the CD11b -cells (mainly tumor cells) (Fig. 5C ). These data suggest that GAMs are the main source of IL-6 in gliomas.
Discussion
The GSCs and microglia/macrophages. GSCs recruit more GAMs than the bulk glioma cells (non GSCs) by releasing higher level of chemoattractants including CCL2 and VEGF-A. In both primary human gliomas and orthotopical transplanted syngeneic glioma, the density of GAMs at the invasive front is increased by the presence of CD133 + GSCs. The interdependence of these two cell types became evident since GAMs release TGF-ß1, which promotes the upregulation of MMP-9 in GSCs and thus tumor invasion (49) . In the present study, we found that CD133 + GSCs trigger IL-6 release from microglia which promotes glioma growth.
Microglia associated with glioma have been assigned the M2 phenotype, since they are tumorsupportive and immune-suppressive (50) . However, in a recent microarray study we demonstrated that GAMs share markers of both the M1 and M2 phenotype and thus the genetic profile defines them as a unique phenotype (36) . The simple view of separation into the M1 and M2 category has 21 also recently been challenged for macrophages and a more differentiated scheme has been proposed(51). Indeed, IL-6, as a pro-inflammatory cytokine, is not upregulated in microglia associated with both mouse and human gliomas compared to naive microglia (26, 52) . We confirmed this finding by stimulating primary microglia with conditioned medium from GL261 cells, and we also did not detect any induction of pro-inflammatory cytokines. GSCs, however, lead to a selective upregulation of IL-6, but not of a battery of other cytokines including TNF-α.
Thus, microglial cells associated with GSCs acquire a phenotype, which is distinct from other glioma-associated microglia. GAMs are thus a heterogeneous population imposed by glioma heterogeneity. Recently it was shown by a single cell sequencing approach, that glioma cells are heterogenic also with respect to the classical diagnostic categories(53).
We found that TLR4 signaling in the microglia/macrophages is essential for IL-6 secretion since release was abolished in TLR4-deficient mice and in a mouse line deficient for the TLR-adaptor protein MyD88, which is an essential component for TLR signaling. Moreover, the anti-TLR4 monoclonal antibody MTS510 inhibited GSC conditioned medium-driven microglial IL-6 secretion. We thus propose that glioma cells release ligands that activate TLR4 signaling. We measured the levels of eleven TLR4 specific ligands in CD133 + and CD133 -cells and identified tenascin-C (TNC) as a possible candidate mediating the IL-6 release in microglia via TLR4
signaling. This is in line with recent findings where TNC was reported as a stem cell marker in human glioma samples (54) . Whereas TNC is produced by stromal fibroblasts in the majority of solid tumors, brain tumor cells themselves are the main source of extracellular matrix TNC in glial malignancies (55, 56) . The intensity of TNC expression is shown to correlate with glioma grade and patient prognosis (55, 57) . Due to its expression in solid tumors, TNC has been used as a tumor-associated antigen to deliver antibody-conjugated radiotherapeutic agents to GBM (58) .
While the classic ligand for TLR4, LPS, triggers the release of several pro-inflammatory Our results are in line with a study where it was demonstrated that interfering with IL-6 signaling in GSCs led to reduced growth and neurosphere formation capacity, and to an increase in the apoptosis rate (27) . From a clinical perspective, the expression of IL-6 and its receptors in the human glioma tissues is inversely correlated to patient survival. The median survival times were 16 months in patients with negative IL-6 expression and 7 months in those with positive IL-6 expression(61). An IL-6 neutralizing antibody attenuated microglia-stimulated glioma 23 invasiveness and reduced glioma growth in vivo (27, 30) . Our data further corroborates the important role of microglial IL-6 in glioma growth. Specifically, we propose that TLR4 signaling is an important component of GSC-microglia crosstalk and propose tenascin-C released by glioma CD133 + cells as a regulator of this pathway (Fig. 6) . TNF-α (B) and IL-1β (C) were also analyzed in a similar way. LPS was used as a positive control. We also determined the cytokine levels of the conditioned media from different cells before application to microglia. hours. We also determined the cytokine levels of the conditioned media from different cells before application to microglia. 
Figure legends
